Federal contract award
HHSN26100003
IGF::OT::IGF NEXT NX232-107-158-006 TO#3 MILESTONE 3 (BASE) - PK&BIOAVAIL STUD W/SELECTED ANTICANCER COMPAOUNDS IN MICE, PK&PHARM EVALS OF AGENTS BEING DEVELOPED FOR CANCER PATIENTS, HHSN261201600024I, DTP-17-035 TPB 8/4/2017 - 6/30/2021
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541990 — All Other Professional, Scientific, and Technical Services |
| PSC | B504 — Chemical/Biological Studies and Analysis |
| Parent award / vehicle | HHSN261201600024I |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $167.1K |
| Current contract value | $167.1K |
| Potential contract value / ceiling | $167.1K |
| Start date | Aug 7, 2017 |
| Current end date | Jun 30, 2021 |
| Potential end date | Jun 30, 2021 |
| Latest award activity | Feb 1, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Feb 1, 2024 | P00004 | $-0 | NEXT NX232-107-158-006 TO#3 MILESTONE 3 (BASE) - PK & BIOAVAIL STUD W/SELECTED ANTICANCER COMPOUNDS IN MICE, PK & PHARM EVALS OF AGENTS BEING DEVELOPED FOR CANCER PATIENTS, HHSN261201600024I/HHSN26100003, DTP-17-035 TPB |
| Feb 25, 2019 | P00003 | $100.3K | NEXT NX232-107-158-006 TO#3 MILESTONE 3 (BASE) - PK&BIOAVAIL STUD W/SELECTED ANTICANCER COMPOUNDS IN MICE, PK&PHARM EVALS OF AGENTS BEING DEVELOPED FOR CANCER PATIENTS, HHSN261201600024I/HHSN26100003, DTP-17-035 TPB |
| Dec 18, 2018 | P00002 | $16.7K | NEXT NX232-107-158-006 TO#3 MILESTONE 3 (BASE) - PK&BIOAVAIL STUD W/SELECTED ANTICANCER COMPOUNDS IN MICE, PK&PHARM EVALS OF AGENTS BEING DEVELOPED FOR CANCER PATIENTS, HHSN261201600024I/HHSN26100003, DTP-17-035 TPB 8/7/2017 - 6/30/2021 |
| Aug 20, 2018 | 1 | $33.4K | NEXT NX232-107-158-006 TO#3 MILESTONE 3 (BASE) - PK&BIOAVAIL STUD W/SELECTED ANTICANCER COMPOUNDS IN MICE, PK&PHARM EVALS OF AGENTS BEING DEVELOPED FOR CANCER PATIENTS, HHSN261201600024I/HHSN26100003, DTP-17-035 TPB 8/7/2017 - 6/30/2021 |
| Aug 3, 2017 | 0 | $16.7K | IGF::OT::IGF NEXT NX232-107-158-006 TO#3 MILESTONE 3 (BASE) - PK&BIOAVAIL STUD W/SELECTED ANTICANCER COMPAOUNDS IN MICE, PK&PHARM EVALS OF AGENTS BEING DEVELOPED FOR CANCER PATIENTS, HHSN261201600024I, DTP-17-035 TPB 8/4/2017 - 6/30/2021 |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.